Physician profile
Richard Carter
NPI 1508065269
$1,488.63
in general payments reported to CMS, 2019-2025
20 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2021: $145 · 2022: $224 · 2023: $388 · 2024: $373 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $444.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $210.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $144.59 | 2023-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $104.58 | 2021-2024 | |
| Atricure, INC. | $95.29 | 2021-2022 | |
| Pfizer INC. | $94.88 | 2019-2023 | |
| Dexcom, INC. | $72.00 | 2023-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $67.15 | 2022-2025 | General - Erectile Dysfunction, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $43.92 | 2023-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $28.02 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.20 | 2022 | |
| Abbott Laboratories | $23.14 | 2025 | Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.18 | 2019 | |
| Corcept Therapeutics | $20.25 | 2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $18.60 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $18.37 | 2024 | |
| Acadia Pharmaceuticals INC | $15.41 | 2021 | |
| Eisai INC. | $13.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.